Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Insight Molecular Diagnostics Inc. (IMDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-incorporated public company listed on Nasdaq, Insight Molecular Diagnostics files current and periodic reports that describe its financial condition, governance decisions, and key developments in its precision diagnostics business.
Through forms such as 8-K, investors can review announcements related to executive compensation changes, stock option grants under the company’s equity incentive plan, amendments to employment agreements, and other material events. Earnings-related 8-K filings furnish press releases that summarize quarterly financial results and business updates, including progress on the GraftAssure dd-cfDNA transplant testing platform.
In addition to current reports, users can locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy materials that address governance matters and executive compensation. These filings provide context on how Insight Molecular Diagnostics manages its transplant-focused diagnostics programs, quality and regulatory activities, and broader corporate strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major topics without reading every page. Real-time updates from EDGAR ensure that new IMDX filings, including any future registration statements or insider transaction reports on Form 4, are added as they become available. This page is a central resource for analyzing the regulatory record of Insight Molecular Diagnostics and its dd-cfDNA-based diagnostics business.
Insight Molecular Diagnostics Inc. Chief Financial Officer James Andrea reported routine equity compensation activity. On March 26, 2026, 28,302 Restricted Stock Units (RSUs) vested into an equal number of common shares under the company’s 2018 Equity Incentive Plan.
The company withheld 11,298 common shares at $4.11 per share to cover required tax obligations, and the filing states that the reporting person did not sell any shares. After these transactions, he directly holds 206,060 common shares and 84,905 RSUs. The RSU award vests over four years, with 25% vesting on March 26, 2026 and the remaining 75% vesting in equal annual installments, subject to continued service.
Insight Molecular Diagnostics Inc. reported that VP, Controller and Treasurer Liu James Yang had restricted stock units vest into 6,289 shares of common stock on March 26, 2026 under the 2018 Equity Incentive Plan. The company withheld 2,578 shares at $4.11 per share to cover tax obligations, and no shares were sold. After these transactions, Yang directly holds 3,711 shares of common stock and 12,578 restricted stock units, with the remaining units scheduled to vest over the next two years, subject to continued service.
Insight Molecular Diagnostics CEO Josh Riggs reported a compensation-related stock transaction involving restricted stock units (RSUs). On March 26, 2026, 47,170 RSUs vested and were converted into the same number of common shares at an exercise price of $0.00 per share under the company’s 2018 Equity Incentive Plan.
To cover required tax withholding on this vesting, 12,310 common shares were withheld by the company at $4.11 per share. The filing states that Riggs did not sell any shares; the disposition was solely for tax obligations. Following these transactions, he directly held 38,365 common shares, and the remaining 75% of the original RSU award is scheduled to vest in equal installments over the next three years, subject to continuous service.
Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on molecular tests for transplanted organ rejection, supported by an intellectual property portfolio in transplant and oncology. Its flagship GraftAssure family measures donor-derived cell-free DNA, offered as a CLIA-lab test and kitted products developed with Bio-Rad.
In 2025 the company began a clinical trial for its GraftAssureDx in vitro diagnostic kit and submitted a data package to the FDA on March 25, 2026, initially targeting kidney transplants. CMS provides coverage for GraftAssureCore and increased reimbursement to $2,753 per result.
The 10-K highlights continued operating losses, with a net loss of $50.2 million in 2025 and an accumulated deficit of $400.8 million, and notes reliance on external financing until test revenues can cover expenses. Key risks include limited near-term revenue concentration in a few tests, intense competition, reimbursement uncertainty, extensive regulatory requirements in the U.S. and abroad, and the need to protect and enforce patents and trade secrets. The company had 58 employees as of December 31, 2025.
Insight Molecular Diagnostics Inc. reported fourth quarter and full-year 2025 results and highlighted major milestones for its GraftAssure transplant diagnostics platform. Full-year net revenue was $4.1 million with gross profit of $2.3 million at a 56.7% gross margin, while the company recorded a net loss of $50.2 million.
Operating expenses were $53.4 million in 2025, including a $14.6 million non-cash impairment of oncology intangible assets, and non-GAAP operating expenses rose 37% year over year. Cash, cash equivalents and restricted cash totaled $12.9 million at year-end, and in February 2026 the company completed a $26.0 million registered direct offering with net proceeds of about $24.6 million.
The company submitted its GraftAssureDx kidney transplant rejection test for FDA de novo review, expects a 150-day review timeline under FDA guidance, and is targeting U.K. CE marking in Q2 2026. It is engaging 37 U.S. and 11 international transplant centers, has secured favorable head-to-head study data versus centralized competitors, and is investing in sales and marketing as it transitions toward commercialization.
Insight Molecular Diagnostics Inc. entered into a material Specimen Collection Agreement with Quest Diagnostics Incorporated on February 20, 2026. Quest Diagnostics will provide specimen collection-related services for samples on which Insight will perform its GraftAssureCore™ blood test, which measures donor-derived cell free DNA using a PCR-based platform.
The parties also agreed that, for a specified period, they will use commercially reasonable efforts to negotiate in good faith additional rights related to the GraftAssure technology. Fees will be paid to Quest Diagnostics for the services under this agreement.
Insight Molecular Diagnostics Inc. saw a major shareholder deepen its stake through a new stock purchase agreement. Broadwood Partners, Broadwood Capital and Neal C. Bradsher reported beneficial ownership of 12,081,932 to 12,082,089 common shares, equal to 37.4% of the company’s stock based on 32,297,028 shares outstanding.
On February 10, 2026, Broadwood Partners agreed to acquire an additional 521,739 shares from the company in a registered direct offering at $5.75 per share, for a combined purchase price of $2,999,999. The investors state the shares are held for investment and may engage with management and other shareholders on ways to enhance long-term value.
Insight Molecular Diagnostics Inc. reported that Broadwood Partners, L.P., a 10% owner, bought additional shares of its common stock. On February 10, 2026, Broadwood Partners agreed to acquire 521,739 common shares from the company in a registered direct offering for $2,999,999, or $5.75 per share, bringing its reported beneficial ownership to 11,931,839 shares.
The filing notes that these shares are directly owned by Broadwood Partners and may be deemed beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher, who each disclaim beneficial ownership beyond their economic interest. The group also reports warrants currently exercisable for 150,093 common shares.
Insight Molecular Diagnostics Inc. entered into securities purchase agreements with institutional investors for a registered direct offering of 3,482,498 common shares and pre-funded warrants to purchase up to 1,043,478 shares at $5.75 per share (or $5.7499 per pre-funded warrant).
The transaction is expected to generate aggregate gross proceeds of approximately $26.0 million and net proceeds of about $24.5 million after placement fees and expenses. The company plans to use the funds for general corporate purposes, focusing on transplantation R&D and expanding its GraftAssure product line, including heart transplant rejection testing.
The pre-funded warrants carry a $0.0001 exercise price and are exercisable until fully exercised, subject to a beneficial ownership cap of 4.99% or, at the holder’s election, 9.99% of outstanding common stock, adjustable with at least 61 days’ prior notice.
Insight Molecular Diagnostics Inc. is conducting a primary offering of 3,482,498 shares of common stock and pre-funded warrants to purchase up to 1,043,478 additional shares of common stock. The shares are priced at $5.75 each and the pre-funded warrants at $5.7499, for gross proceeds of $26,024,257.65. Net proceeds are expected to be approximately $24.5 million after placement fees and expenses. The company plans to use the cash mainly for general corporate purposes and research and development in transplantation, including expanding its GraftAssure transplant rejection testing from kidneys into other organs, most immediately heart. Assuming full exercise of the pre-funded warrants, shares outstanding would be 33,151,381, and the transaction increases net tangible book value from $(0.83) to $0.02 per share, implying dilution of $5.73 per share to new investors.